News Sentiment

ABOS sentiment intelligence

Acumen Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 59 Balanced news tone 54 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.63 Week of 10 Jul 2026
Weighted tone 59/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

84/100 classification confidence.

Company focus 46

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-4.0% over one week, +11.0% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Positive

All You Need to Know About Acumen Pharmaceuticals (ABOS) Rating Upgrade to Buy

Market Reaction

Price moving ahead of tone

70/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 84/100 classification
One-week reaction -4.0% Price reacting lower
Trend fit Trend inactive 11.0% over four weeks
Fair value 0.3% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 21
Neutral 29
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 46
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 12
Market source 10
TradingView 5
TradingKey 3
Exec Edge 2
The Manila Times 2
www.marketscreener.com 2
MT Newswires 2

Event Lens

What the news is about

Classified themes
Market update 36
Earnings 11
Analyst action 2
Balance sheet 2
Deals and strategy 2
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 54
The Manila Times Direct company coverage

Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ (EBD™) Program Data and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026

Acumen Pharmaceuticals presented new data at AAIC 2026 demonstrating enhanced brain delivery of its anti-AβO antibodies through its Enhanced Brain Delivery™ (EBD™) program, showing improved brain penetration in non-human primates. The company's EBD candidate ACU401 achieved signi

Tone
Positive 74/100
Event
Market update
Published
15 Jul 2026 11:14
Source
The Manila Times
Stock Titan Direct company coverage

38 Early Alzheimer's Participants Describe Memory and Social Challenges

Acumen Pharmaceuticals presented new data at AAIC® 2026, highlighting significant advancements in its Enhanced Brain Delivery™ (EBD™) program with bispecific antibodies achieving up to 40-fold higher brain exposure in non-human primates. Simultaneously, insights from 38 early Alz

Tone
Positive 72/100
Event
Market update
Published
15 Jul 2026 11:14
Source
Stock Titan
ACCESS Newswire Direct company coverage

Acumen Pharmaceuticals and Unlearn Collaborate to Explore Analyses of Alzheimer's Disease Clinical Programs

Acumen Pharmaceuticals and Unlearn have partnered to apply Unlearn's AI-generated digital twin technology to Acumen's Alzheimer's disease clinical trials. This collaboration aims to leverage digital twins, which are comprehensive forecasts of individual trial participants' outcom

Tone
Positive 76/100
Event
Balance sheet
Published
09 Jul 2026 09:40
Source
ACCESS Newswire
The Manila Times Direct company coverage

Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026

Acumen Pharmaceuticals is set to present three key studies at the Alzheimer's Association International Conference (AAIC®) 2026 in London. The presentations will cover findings on their Enhanced Brain Delivery (EBD™) technology developed in collaboration with JCR Pharmaceuticals,

Tone
Positive 74/100
Event
Market update
Published
08 Jul 2026 11:40
Source
The Manila Times
Stock Titan Direct company coverage

Acumen to show brain-delivery data and patient insights at AAIC 2026

Acumen Pharmaceuticals will present three studies at the Alzheimer's Association International Conference (AAIC) 2026 in London from July 12-15, 2026. These presentations will cover data on their Enhanced Brain Delivery (EBD) bispecific antibodies, which utilize transferrin-recep

Tone
Positive 73/100
Event
Market update
Published
07 Jul 2026 11:09
Source
Stock Titan
TradingView Direct company coverage

Number of shareholders of Acumen Pharmaceuticals, Inc. – NASDAQ:ABOS

This article provides a brief overview regarding the number of shareholders for Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS). It appears to be a stub or a section focused solely on the "Number of shareholders" value, which is not populated in the provided content. The article is p

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 12:40
Source
TradingView
Traders Union Direct company coverage

Acumen Pharmaceuticals, Inc. commits to advancing targeted therapies for Alzheimer care

Acumen Pharmaceuticals, Inc. has reaffirmed its dedication to developing targeted treatments for Alzheimer's disease, emphasizing its support for affected individuals and their families. The company's ongoing research aims to preserve meaningful life moments for patients and care

Tone
Positive 72/100
Event
Market update
Published
01 Jul 2026 08:40
Source
Traders Union
www.marketscreener.com Direct company coverage

Acumen Pharmaceuticals, Inc.(NasdaqGS: ABOS) added to Russell 2000 Index

Acumen Pharmaceuticals, Inc. (NasdaqGS: ABOS) has been added to the Russell 2000 Index, as well as the Russell 2000 Value Benchmark, Russell Small Cap Comp Value Benchmark, Russell 2500, Russell 2500 Value, and Russell 3000 Indices. The company, a clinical-stage biopharmaceutical

Tone
Positive 71/100
Event
Market update
Published
29 Jun 2026 22:09
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Acumen Pharmaceuticals, Inc.(NasdaqGS: ABOS) added to Russell 2500 Index

Acumen Pharmaceuticals, Inc. (NasdaqGS:ABOS) has been added to the Russell 2500 Index, as announced on June 28, 2026. This inclusion reflects the company's growing presence in the market and follows its recent addition to several other Russell indices, including the Russell 2000

Tone
Positive 75/100
Event
Market update
Published
29 Jun 2026 21:09
Source
www.marketscreener.com
marketscreener.com Direct company coverage

Acumen Pharmaceuticals, Inc.(NasdaqGS: ABOS) added to Russell 2000 Value Benchmark

Acumen Pharmaceuticals, Inc. (NasdaqGS: ABOS) has been added to the Russell 2000 Value Benchmark. The company, a clinical-stage biopharmaceutical firm, focuses on developing treatments for Alzheimer's disease, including its lead immunotherapy drug candidate, sabirnetug (ACU193).

Tone
Positive 73/100
Event
Market update
Published
29 Jun 2026 15:40
Source
marketscreener.com
TradingView Direct company coverage

Acumen Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:ABOS)

This article provides an overview of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) with financial actuals and estimates. It covers the current stock price, historical performance, analyst forecasts, market capitalization, upcoming earnings reports, and other key financial data. The

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 23:42
Source
TradingView
TradingView Direct company coverage

ABOS Forecast — Price Target — Prediction for 2027

This article provides a forecast for Acumen Pharmaceuticals, Inc. (ABOS) stock, including price targets from analysts, historical performance data, and financial metrics. It highlights that analysts have a maximum estimate of $10.00 and a minimum estimate of $4.00 for the stock's

Tone
Neutral 50/100
Event
Guidance
Published
25 Jun 2026 17:42
Source
TradingView
BioSpace Direct company coverage

JCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer’s Disease, Enabled by J-Brain Cargo® Technology Platform

JCR Pharmaceuticals announced that Acumen Pharmaceuticals has exercised its exclusive option to develop, manufacture, and commercialize up to two Alzheimer's disease therapeutic candidates using JCR's J-Brain Cargo® technology platform. This partnership aims to create a blood-bra

Tone
Positive 72/100
Event
Deals and strategy
Published
18 Jun 2026 06:40
Source
BioSpace
TradingKey Direct company coverage

Acumen Pharmaceuticals Inc (ABOS) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides a historical overview of dividends and stock splits for Acumen Pharmaceuticals Inc (ABOS). It indicates that the company has not distributed any dividends over the past five years and has no record of stock splits. The financial data displayed current stock p

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 02:39
Source
TradingKey
Investing.com Direct company coverage

Acumen Pharmaceuticals director Porter sells $75,239 in stock

Derrell Porter, a director at Acumen Pharmaceuticals, sold $75,239 worth of common stock between June 15 and June 17, 2026, at prices ranging from $2.325 to $2.345 per share. Prior to these sales, Porter acquired shares through the exercise of stock options at $1.07 per share. Fo

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 23:40
Source
Investing.com
TradingKey Direct company coverage

Acumen Pharmaceuticals Inc (ABOS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution — TradingKey

This article from TradingKey provides an overview of Acumen Pharmaceuticals Inc (ABOS) with a focus on its market capitalization and current stock price. It highlights that detailed revenue breakdown data by business segments and regions have not yet been disclosed by the company

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 21:39
Source
TradingKey
Stock Titan Direct company coverage

Acumen Pharmaceuticals (ABOS) director sells 32,300 shares after exercising options

Derrell Porter, a director at Acumen Pharmaceuticals (ABOS), exercised options for 19,500 shares and subsequently sold 32,300 shares of common stock between June 15-17, 2026. The exercised options were priced at $1.07 per share, while the sales occurred at weighted average prices

Tone
Negative 37/100
Event
Market update
Published
17 Jun 2026 21:39
Source
Stock Titan
grafa.com Direct company coverage

Acumen exercises option for JCR brain technology

Acumen Pharmaceuticals has exercised its exclusive option with JCR Pharmaceuticals to develop and commercialize two Alzheimer’s disease candidates using JCR's J-Brain Cargo platform. This collaboration aims to deliver therapeutic antibodies across the blood-brain barrier for bett

Tone
Positive 73/100
Event
Market update
Published
17 Jun 2026 20:39
Source
grafa.com
Stock Titan Direct company coverage

Acumen bets on JCR’s brain-barrier tech for Alzheimer’s drug candidates

Acumen Pharmaceuticals has exercised its exclusive option with JCR Pharmaceuticals to develop, manufacture, and commercialize up to two Alzheimer's disease drug candidates using JCR's J-Brain Cargo® technology. This strategic partnership, announced in July 2025, aims to create a

Tone
Positive 75/100
Event
Deals and strategy
Published
17 Jun 2026 16:39
Source
Stock Titan
Investing.com South Africa Direct company coverage

Acumen nominates two Alzheimer’s candidates for development By Investing.com

Acumen Pharmaceuticals Inc. has nominated two Alzheimer’s drug candidates, ACU301 and ACU401, for development using its amyloid beta oligomer-selective antibody technology combined with JCR Pharmaceuticals' J-Brain Cargo platform for enhanced brain delivery. Preclinical studies s

Tone
Positive 65/100
Event
Market update
Published
17 Jun 2026 02:11
Source
Investing.com South Africa
Stock Titan Direct company coverage

ABOS (NASDAQ: ABOS) Form 144 shows proposed sale of 12,800 shares

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) has submitted a Form 144 filing indicating a proposed sale of 12,800 shares of restricted common stock. The filing also reports that 6,460 shares were sold on June 15, 2026, for proceeds of $15,148.70, with Morgan Stanley Smith Barney L

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 21:09
Source
Stock Titan